Final results of CLL11 confirm superiority of obinutuzumab

Obinutuzumab (GA101; G) is a glycoengineered type II anti-CD20 monoclonal antibody. The randomized phase III CLL11 study compared G plus chlorambucil (Clb) to rituximab (R) plus Clb and to Clb alone in 781 patients with previously untreated CLL and comorbidities, with a median age of 73 years. Previous analyses demonstrated PFS superiority of G-Clb over R-Clb, but for OS statistical significance was not reached.

The final analysis, with a median observation time of approximately 60 months, now demonstrates that treatment with G-Clb results in a clinically meaningful improvement of outcome as compared to R-Clb, as was presented during the Presidential symposium by Dr Valentin Goede (University Hospital Cologne, Germany).

“We did not detect any new late-onset toxicity signals in this final analysis”, Goede said. “Importantly, the rate of fatal adverse events was not higher in the G-arm.” Median PFS was 28.9 months with G-Clb versus 15.7 months with R-Clb (HR 0.49, p<0.0001). This translated in an improvement of time to next treatment (median 56.4 vs 34.9 months, respectively).

Goede: “The final analysis of the CLL11 trial demonstrated a statistically significant prolonged OS in the G-arm compared to the R-arm. Median OS in the R-arm was 73.1 months, whereas in the G-arm it was not reached (HR 0.76, p=0.0245). This difference is clinically meaningful, and also remarkable in the context of the long follow-up given the fact that half of the patients have received at least one salvage treatment in the meantime.”

Visit the EHA Learning Center to view the abstract.

Visit the EHA Learning Center to view the webcast.

Last Updated on Friday 03 August 2018.